Structural brain imaging and multivariate analysis enable virtual lumbar punctures
Functional brain imaging has been a standard tool in the basic and clinical neurosciences for at least 2 decades, and structural brain imaging can claim an even longer track record of successful use for diagnosis of neurodegenerative disease. It is instructive to recall the ways in which brain imaging has been used to date, and this exercise will clarify why the contribution by McMillan et al. 1 in the current issue of Neurology ® is exciting and novel.
Most diagnostic uses of structural brain images to date have involved naked-eye diagnostics or focal univariate techniques for which specific areas in the brain are probed for their cortical thickness, volume, or gray matter density, to identify patients in the prodromal or early stages of neurodegenerative disease. Functional neuroimaging analytic tools have been largely univariate also, mapping the neural substrates of cognitive operations, subjects' states/traits, or other variables of interest. These analytic tools have, however, recently been augmented by more complex multivariate techniques that look at brain-wide atrophy or activation patterns. 2 Together with this increasing sophistication of analytic tools, neuroimaging has recently experienced a reversal of the research goals under the rubric of "brain reading" 326 : rather than mapping the neural substrates of a known subject variable in brain-imaging data, such as, for instance, behavioral performance in a cognitive task or diagnostic status of a neurodegenerative disease, the goal has become to predict a priori unknown subject information from the brain-imaging data.
Brain-reading approaches have mainly been applied to problems in basic cognitive neuroscience, but they are naturally highly relevant for diagnostic applications too. For the derivation of imaging-based biomarkers, brain-reading approaches provide clear performanceassessment metrics: rather than relying on complex and often assumption-laden statistical inference and model estimation in the mapping enterprise, one can empirically check how the biomarker predicts the outcome of interest on test data for which the outcome is known a priori. This is conceptually elegant, and McMillan et al. 1 showcase a nice example in their current Neurology ® article: with a simple multivariate technique, the authors were able to derive a structural brain pattern from MRI that predicts the diagnostically important ratio of total tau (tt) and b-amyloid (Ab 1-42 ) (tt/Ab) using a cohort of patients with Alzheimer disease (AD) and frontotemporal lobar degeneration (FTLD). Analytes of these 2 proteins usually have to be obtained from a sample of CSF, which must be acquired through an invasive and possibly painful lumbar-puncture procedure. The results of McMillan et al. are impressive: the tt/Ab ratio inferred from the MRI data correlated well with the measured tt/Ab ratio, and in a small cohort of pathologically or genetically confirmed patients was able to correctly classify patients with AD vs FTLD pathology with an accuracy of 75%. This classification accuracy was comparable to that achieved with the measured tt/Ab ratio. Importantly, the clinical diagnoses of the patients with AD and FTLD overlapped substantially, demonstrating utility for predicting pathology in clinically atypical patients in which diagnosis is the most challenging.
These findings build on a body of work demonstrating that MRI could have an important role in predicting pathologic diagnosis. 7 The current report describes a somewhat indirect approach of utilizing MRI to predict a CSF biomarker ratio that serves as a proxy for pathology, although it does seem to perform reasonably well against the pathologic gold standard. Atrophy in the posterior cortices of the brain on MRI is particularly predictive of AD pathology in patients with atypical clinical presentations, 8, 9 and McMillan et al. 1 similarly showed that these patterns were predictive of high tt/Ab. Conversely, atrophy in frontal and anterior temporal lobes is more predictive of FTLD, 7 as well as low tt/Ab. 1 The advantage of the multivariate approach of McMillan et al. over previous univariate studies is that these complex MRI patterns can be summarized with a single diagnostically useful value that could potentially be applied in a clinical setting. One could also see how such a value could aid patient selection for future clinical trials that target these pathologies.
However, an empirical test of the tt/Ab prediction from brain data in an independent sample will be an important additional step before this method could be confidently applied to other cohorts. The authors did a thorough job in their derivation and used several safeguards to avoid "overfitting," i.e., using an overly complex model that seems to work well in the derivation data set, but performs poorly in independent data. However, the true test has to be performed on independent data that were not used in the construction of the biomarker in the first place: ideally, in this case, an independent data set that represents the spectrum of FTLD pathologies, so as to ensure the results were not biased by a particular combination of pathologies. Building on the good start of McMillan et al., we are confident this will happen in the near future. The longitudinal stability and predictive accuracy of the MRI-predicted tt/Ab ratio throughout the disease course will also require further clarification before it can be applied to heterogeneous clinical cohorts.
McMillan et al. successfully demonstrate that a multivariate MRI-based approach can be used to estimate CSF tt/Ab and hence provide good prediction of underlying pathology in these neurodegenerative diseases. The study also provides an instructive example that could be embraced and copied for other types of diagnostically relevant but hard-to-get physiologic information. Powerful and user-friendly software tools already exist in the public domain 10 and could readily be used by clinicianscientists. The initial investment of familiarization with such tools will be well worth the payoff. 
